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the outcome of periampullary adenocarcinomas remains poor with few treatment options. 
podocalyxin-like protein (poDXL) is an anti-adhesive protein, the high expression of which has been 
shown to confer a poor prognosis in numerous malignancies. A correlation and adverse prognostic 
synergy between poDXL and the epidermal growth factor receptor (eGfR) has been observed in 
colorectal cancer. Here, we investigated whether this also applies to periampullary adenocarcinomas. 
We analyzed the immunohistochemical expression of poDXL and eGfR in tissue microarrays with 
tumors from two patient cohorts; (Cohort 1, n = 175) and (Cohort 2, n = 189). The effect of TGF-
β-induced expression and siRnA-mediated knockdown of poDXL and eGfR, were investigated in 
pancreatic cancer cells (PANC-1) in vitro. We found a correlation between poDXL and eGfR in these 
cancers, and a synergistic adverse effect on survival. Furthermore, silencing PODXL in pancreatic cancer 
cells resulted in the down-regulation of EGFR, but not vice versa. Consequently, these findings suggest 
a functional link between poDXL and eGfR, and the potential combined utility as biomarkers possibly 
improving patient stratification. Further studies examining the mechanistic basis underlying these 
observations may open new avenues of targeted treatment options for subsets of patients affected by 
these particularly aggressive cancers.
The periampullary region includes the head of the pancreas, the distal bile duct, the ampulla of Vater and the peri-
ampullary duodenum. Adenocarcinomas developing in this region represent a heterogeneous group of tumors, 
wherein morphology appear to provide more prognostic information than the tumor origin, in that pancreatobil-
iary type (PB-type) differentiation is associated with a significantly shorter survival than intestinal type (I-type)1,2. 
Pancreatic cancer, the most common type of periampullary adenocarcinomas, has a 5-year overall survival of 
merely 7%3, the dismal prognosis partly due to a high rate of advanced tumor stages at the time of diagnosis4.
Podocalyxin-like protein (PODXL) is a member of the CD34 family of transmembrane glycoproteins consist-
ing of a mucin-like extracellular domain and a cytoplasmic tail. PODXL is expressed on podocytes and the apical 
surface of glomerular epithelial cells of the kidney5, where it plays an important role in maintaining adequate 
filtration6, due to its anti-adhesive properties. Moreover, PODXL is involved in the regulation of cell adhesion 
and is expressed for instance on vascular endothelia7 and hematopoietic progenitor cells8,9. Aside from these 
normal conditions, PODXL has been found to be upregulated in various malignancies, and its strong expression, 
particularly in the cell membrane, associates with a more aggressive tumor phenotype and a poor prognosis in 
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periampullary10, breast11, colorectal12–15 ovarian16, and bladder cancers17, as well as in glioblastoma18. The role of 
PODXL in tumorigenesis is unclear, but evidence suggests that PODXL is involved in epithelial-mesenchymal 
transition (EMT), a process by which epithelial cells acquire invasive and migratory properties and make them 
resistant to apoptosis19. EMT is regulated by various differentiation and growth factors, most importantly trans-
forming growth factor β (TGF-β). When TGF-β is added to epithelial cells in culture, EMT will be induced20.
The epidermal growth factor receptor (EGFR) is a glycoprotein and a tyrosine kinase receptor, which 
belongs to the human epidermal growth factor receptor (HER) family. EGFR activation induces intracellular 
signaling-cascades important for growth, differentiation and cell survival21, all essential for tumor development. 
EGFR overexpression is common in several malignancies including cancers of the breast, ovary, bladder, kidney, 
lung and brain21. In pancreatic cancer, EGFR has been found to be overexpressed in 30–95% of the cases22,23 and 
associated with a poor prognosis24. Previous work has shown that high expression of PODXL and EGFR impair 
survival in colorectal cancer in a synergistic way25. This study thus aimed to investigate the relationship between 
the expression of PODXL and EGFR in periampullary adenocarcinomas, including pancreatic cancer, with focus 
on morphological subtypes. We also examined the functional interplay between PODXL and EGFR in pancreatic 
cancer cells in vitro.
Methods
patients. Cohort 1. Cohort 1 is a previously described retrospective consecutive cohort of 175 patients 
with primary periampullary adenocarcinomas who were surgically treated with pancreaticoduodenectomy at 
the University hospitals of Lund and Malmö, Sweden, from 1 January 2001 through 31 December 201110,26–29. 
Morphologically, 110 cases were classified as PB-type and 65 cases as I-type adenocarcinomas. Fortysix of these 
175 patients presented with pancreatic ductal adenocarcinoma. Data on survival were gathered from the Swedish 
National Civil Register and clinical data was obtained retrospectively from medical records. Follow-up began 
on the date of surgery and ended upon death or upon the final update in March 2017. Patients were identified 
through broad searches in the pathology database, and all haematoxylin and eosin (H&E) stained slides were 
re-evaluated by one pathologist (JEL), blinded to the original report and outcome, with the decision on tumor 
origin and morphological type being based on several criteria, as previously described26. The Ethics Committee 
of Lund University (ref no. 445/07) approved the study, whereby the committee waived the need for consent other 
than by opting out. Methods were carried out in accordance with relevant guidelines and regulations.
Cohort 2. Cohort 2 is a previously described retrospective cohort of 189 consecutive patients with pancre-
atic ductal adenocarcinoma undergoing surgery at the Department of Surgery, Helsinki University Hospital in 
Finland from 1 January 2000 through 31 December 201130,31. A majority of the tumors were of periampullary 
origin, however a small number of the tumors originated in cauda pancreatis. Patients who received neoadju-
vant chemotherapy (n = 21) were excluded from the study. Data on survival and cause of death were gathered 
from medical records, Statistics Finland, and the Finnish Population Registry. The Surgical Ethics Committee 
of Helsinki University Central Hospital (Dnro HUS 226/E6/06, extension TMK02 §66 17.4.2013) approved 
the study. Permission to use tissue samples without individual informed consent was granted by the National 
Supervisory Authority of Health and Welfare (Valvira Dnro 10041/06.01.03.01/2012). Methods were carried out 
in accordance with relevant guidelines and regulations.
tissue microarray construction. As previously described for Cohort 110, a semi-automated array-
ing device (TMArrayer, Pathology Devices, Westminister, MD, USA) was used for the construction of tissue 
microarrays (TMAs). Three tissue cores of 1 mm were sampled from each of the 175 primary tumors and from 
lymph node metastases from 105 of the cases. In addition, two tissue cores (1 mm) were obtained from adjacent 
benign-appearing pancreatic tissue in 50 cases with duodenal or ampullary cancer.
For Cohort 2, TMAs were constructed using a semiautomatic tissue microarrayer (Tissue Arrayer 1, Beecher 
Instruments Inc., Silver Spring, MD, USA). Two 1-mm cores were taken from representative areas of each of 
the 168 tumors. Fifteen cases were excluded from analysis due to inadequate or missing cores. All samples were 
re-evaluated by two experienced pathologists. Histological images of the tumor tissues from both cohorts were 
published elsewhere10,28,30.
immunohistochemistry and staining evaluation. For immunohistochemical analysis of PODXL 
expression in Cohort 1, TMA sections of 4 μm were automatically pre-treated using the PT Link system, and 
then stained in an Autostainer Plus (DAKO; Glostrup, Copenhagen, Denmark) with a polyclonal anti-PODXL 
antibody (HPA2110, Atlas Antibodies AB, Stockholm, Sweden, diluted to 1: 250), as described elsewhere10. The 
expression of PODXL was recorded as negative (0), weak cytoplasmic positivity in any proportion of cells (1), 
moderate cytoplasmic positivity in any proportion of cells (2), distinct membranous positivity in ≤50% of cells 
(3) and distinct membranous positivity in>50% of cells (4)10,12–14,17, and dichotomized into low (0–2) or high 
(3–4). Staining evaluation was performed by two independent observers (MH and KJ), who were blinded to the 
clinical and outcome data.
Immunohistochemical technique and PODXL staining evaluation in Cohort 2 were described elsewhere30. 
The same polyclonal antibody (HPA 2110, Atlas Antibodies, Stockholm, Sweden) was used as that in Cohort 1.
For immunohistochemical analysis of EGFR in both cohorts, 4 μm TMA-sections were pre-treated using 
the PT-link system (Dako), and subsequently stained with a monoclonal anti-EGFR antibody (31G7, Zymed 
Laboratories Inc, San Francisco, CA, USA, diluted to 1:25) using the Autostainer Plus (Dako, Glostrup, Denmark). 
The evaluation of the EGFR protein expression in Cohort 1 was described elsewhere28 but was now performed 
on Cohort 2. The evaluation was performed using the recommended protocol for HER2 testing in gastric and 
gastroesophageal junction cancer biopsies32, taking complete, basolateral, or lateral membranous reactivity in a 
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minimum of five clustered positive cancer cells into account. The intensity recorded was rated as 0, 1+, 2+ or 3+. 
Protein expression was grouped into low (0–2+) or high (3+) expression, as described elsewhere28. Cytoplasmic 
staining was grouped as 1+ in the statistical analyses. Staining evaluation was performed by three independent 
observers (MH, AL and KJ). Any inter-observer discrepancies were discussed in order to reach consensus. In 
Cohort 2, 10 cases were excluded from the analyses due to staining or interpretation problems with the EGFR 
antibody.
cell culture. Human pancreatic cancer cell lines PANC-1 and human foetal foreskin fibroblasts (HFFF2) 
were purchased from Sigma-Aldrich and the growth medium, foetal bovine serum (FBS) and antibiotics were 
obtained from Nordic Biolabs. The cells were maintained in an RPMI1640 or DMEM medium supplemented with 
10% FBS and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin) in a humidified 5% CO2 atmosphere 
at 37°C. All in vitro reagents were purchased from ThermoFisher Scientific unless stated otherwise. All in vitro 
experiments were repeated at least three times.
siRnA transfection. Pancreatic cancer cells were seeded in T-25 flasks (5×105 cells) and incubated for 
72 hours in 37°C for siRNA transfection. Subsequently, the cells were washed twice with phosphate buffered 
saline (PBS) and received the medium without FBS, together with lipofectamine 2000 and the negative control, 
anti-PODXL (s10770 + s10771) or anti-EGFR (s563 + s565) siRNA in OptiMEM to a final siRNA concentration 
of 25 nM. After 4.5 hours, the transfection was stopped, and the medium changed to a full-growth medium. The 
cells were then left to recover overnight, and the next day, cells were harvested and spun down to pellets. The 
pellets were either resuspended in Trizol and stored at −20°C for qPCR, or fixated, dehydrated and embedded in 
paraffin for immunohistochemistry.
tGf- β incubation. For TGF-β incubation, pancreatic cancer cells were seeded in T-25 flasks (5×105 cells), 
incubated for 72 hours at 37°C, and then incubated with TGF-β (10 ng/ml) for 48 hours. Following this, the cells 
were harvested and spun down to pellets. The pellets were either resuspended in Trizol and stored at −20°C for 
qPCR, or fixated, dehydrated and embedded in paraffin for immunohistochemistry.
organotypic assay. The method of designing an organotypic assay was described elsewhere33. Twenty-four 
hours after siRNA transfection or TGF-β incubation, the 3D organotypic model was prepared according to 
Moutasim et al. and Froeling et al.34,35. Prior to making the gel (7 parts Collagen I, 1 part DMEM 10×, 1 part FBS 
and 1 part regular DMEM growth medium), inserts (3 μm pores) in a 24-wells plate were coated with collagen. 
The gel was made from 3.5 parts Collagen I, 3.5 parts Matrigel, 1 part DMEM 10×, 1 part FBS and 1 part cell 
suspension (containing 2.5×104 HFFF2 cells) and added to each collagen-coated insert. The gels were left to 
incubate for 1 hour at 37 C, and following gel polymerization, the cancer cells (5×104) were harvested and mixed 
with HFFF2 (2.5×104) and seeded on top of the gels. Subsequently, the medium was added to the wells and the 
organotypic model was incubated overnight at 37 C. After overnight incubation, the medium was removed from 
the wells and inserts and the medium was added to the well up to the bottom of the insert to create an air-liquid 
interface. Every two to three days, the medium was changed, and after incubation for seven days, the gels were 
fixated in 4% paraformaldehyde and paraffin embedded. Sections (3-μm-thick) of the gels were stained with H&E 
for the visualization of cancer cell invasion. For TGF-β incubated cells prior to the model, gel sections were also 
stained for PODXL or EGFR using the same antibodies as those used for tissue samples. Representative pictures 
of one out of three individual repeats were taken with cellSens dimension software at 20x magnification. The rate 
of invasion in the gel was based on estimates of the observed number of cells entering the gel, and not formally 
quantified.
immunohistochemistry. TMAs were constructed from the paraffin-embedded cell pellets, and the stain-
ing of PODXL and EGFR was performed in the same manner as the tissue samples. The cell pellets were used to 
visualize protein expression under the different conditions tested in vitro.
qpcR. The method of qPCR has been described elsewhere33. To remove the cell debris, the cell samples were 
thawed and spun down. According to the manufacturer’s instructions, RNA purification was performed using 
Trizol with phasemaker tubes. Thereafter, RNA cleanup was performed using the RNeasy minelute kit (QIAGEN) 
and the RNA concentration was determined using Qubit with the RNA HS kit. cDNA reverse transcription was 
performed using the high-capacity cDNA reverse transcription kit, prior to qPCR, and the total cDNA concentra-
tion was determined using Qubit with the DNA HS kit. Ten ng per reaction of each sample was used to run qPCR 
with the PODXL or EGFR TaqMan gene expression assay (Assay ID Hs01574644_m1 and Hs01076090_m1, 
respectively), with samples run in triplicates. 18 S served as the endogenous control (Assay ID Hs039288985_g1).
Statistical analysis. In Cohort 1, three patients were excluded from the survival analyses; two with I-type 
adenocarcinomas who died within one month of surgery due to complications and one with PB-type adeno-
carcinoma who emigrated five months after surgery. Another two patients with PB-type adenocarcinomas who 
had received neoadjuvant chemotherapy were excluded from the survival analyses since the treatment might 
have affected the expression of PODXL. The Kaplan Meier analysis and log-rank test were applied to illustrate 
differences in overall survival (OS) with respect to PODXL and EGFR expression. The p-value was based on a 
pairwise comparison. Cox regression proportional hazard models were used to estimate hazard ratios (HRs) for 
death in both univariable and multivariable analysis, adjusted for tumor grade, T-stage (T1–2 vs. T3–4), N-stage 
(N0 vs. N1), perineural growth, blood vessel invasion, lymphatic invasion, the invasion of peripancreatic fat, 
adjuvant treatment, and for morphological type in Cohort 1, and adjusted for tumor grade, T-stage (T1–2 vs. 
T3–4), N-stage (N0 vs. N1), perineural growth, blood vessel invasion, and adjuvant treatment in Cohort 2. The 
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proportional hazard (PH) assumption was tested graphically by using log-minus-log plots. The PH assumption 
was also evaluated using the Cox regression analysis with a time-dependent covariate analysis, whereby the PH 
assumption was considered to be satisfied when the factor-by-time interaction was not significant. All statistical 
analyses were performed using IBM SPSS Statistics version 22.0 (SPSS Inc., Chicago, IL, USA). All tests were 
two-sided and we considered p-values <0.05 significant.
Results
poDXL and eGfR expression. A significant correlation between the expression of PODXL and EGFR was 
identified in both cohorts, as well as in the stratified analysis according to morphological subtype (Fig. 1). The 
associations of clinicopathological factors with PODXL and EGFR expressions in Cohort 110,28 and with PODXL 
in Cohort 230 were described elsewhere.
clinical outcome related to the combined strata of poDXL and eGfR expression. Cohort 1. As 
Fig. 2 shows, the Kaplan-Meier analysis revealed that patients with tumors displaying high levels of both PODXL 
and EGFR exhibited the shortest OS in the entire cohort and in tumors with an I-type morphology. This was, 
however, not seen in PB-type tumors. As shown in Table 1, the high PODXL expression served as an independent 
predictor of a diminished OS across the entire cohort, among both patients with low EGFR tumors (HR 1.84; 
95% CI 1.09–3.12), and among patients with high EGFR tumors (HR 1.78; 95% CI 1.03–3.07). The highest risk 
of death was observed among patients with I-type tumors displaying a high expression of both PODXL and 
EGFR (unadjusted HR 2.90; 95% CI 1.03–8.18), and this association remained significant in the adjusted anal-
ysis (HR 4.77; 95% CI 1.02–22.33). We considered the PH assumption satisfied using the graphic evaluation of 
log-minus-log plots (data not shown). Moreover, the time-dependent covariate was not significant for PODXL 
and EFGR, and therefore, the factor x time interaction term was dropped from the model.
Cohort 2. As demonstrated in Fig. 3, the Kaplan-Meier analysis found that a high PODXL expression, in combi-
nation with a high EGFR expression, correlated with a significantly reduced overall survival (p = 0.017) compared 
to patients without the overexpression of the two proteins. These results mirror those in Cohort 1. However, as 
Figure 1. Correlations between the immunohistochemical expression of PODXL and EGFR. Bar charts 
visualizing the correlations between low vs. high (0 vs. 1) PODXL and low vs. high (0 vs. 1) EGFR. The top row 
shows the correlations for Cohort 1, for the entire cohort and divided into morphological subtypes. The bottom 
row shows the correlations for Cohort 2.
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shown in Table 2, a high PODXL expression did not associate with a reduced overall survival, irrespective of 
EGFR expression.
Effects of TGF-β incubation and the siRnA-mediated silencing of poDXL and eGfR in pancre-
atic cancer cells in vitro. In addition to the results found in both cohorts, functional studies were performed 
in vitro using PANC-1 pancreatic cancer cells either transfected with siRNA against PODXL (siPODXL) or EGFR 
(siEGFR), or incubated with TGF-β. Figure 4A displays the protein expression under different conditions in the 
3D organotypic model and cell pellets. In the top row, where cells were incubated with TGF-β alone, we found an 
increasing invasion following TGF-β incubation. This was visualized in the H&E staining by the greater number 
of cells entering the gel compared to the control. In addition, the expression of PODXL was more prominent 
along the invasive front, however, the protein expression of EGFR was fairly unchanged (second and third row; 
inserts show immunocytochemistry on the cell pellets). Furthermore, the mRNA levels of PODXL and EGFR 
were successfully transiently knocked down in PANC-1 cells by siRNA (Fig. 4B). Here, the siPODXL-transfected 
cells were reduced in both PODXL and EGFR, whereas the siEGFR-transfected cells alone appeared reduced 
in EGFR. Following TGF-β incubation, the PODXL mRNA levels showed a fourfold increase and EGFR was 
somewhat reduced (Fig. 4C). To examine the combined effect of TGF-β and siRNA on PODXL and EGFR expres-
sion, PANC-1 cells were incubated with TGF-β following siRNA transfection (bottom two rows of Fig. 4A, and 
Fig. 4D). As shown in Fig. 4A, EGFR expression disappeared following the combination of siPODXL and TGF-β, 
whereas PODXL expression increased after the combination of siEGFR and TGF-β. This was also visible at the 
mRNA level, where the combination of siPODXL and TGF-β incubation resulted in a reduction in EGFR, and 
siEGFR together with TGF-β greatly enhanced the PODXL expression (Fig. 4D). This confirms that PODXL 
Figure 2. Overall survival according to PODXL and EGFR expressions in Cohort 1. Kaplan-Meier estimates for 
the overall survival according to the combined strata of low and high PODXL and EGFR expression in Cohort 
1, shown for the entire cohort, for PB-type and I-type tumors. The p-value was based on a pairwise comparison 
with PODXL-/EGFR- and PODXL+/EGFR+.
All Pancreatobiliary type Intestinal type
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
n (events) HR (95%CI) HR (95%CI) n (events) HR (95%CI) HR (95%CI) n (events) HR (95%CI) HR (95%CI)
EGFR low
PODXL low 75 (54) 1.00 1.00 40 (36) 1.00 1.00 35 (18) 1.00 1.00
PODXL high 21 (19) 1.84 (1.09–3.12) 1.23 (0.69–2.17) 18 (17) 1.24 (0.69–2.22) 1.15 (0.62–2.14) 3 (2) 1.43 (0.33–6.21) 1.00 (0.11–9.08)
EGFR high
PODXL low 28 (20) 1.00 1.00 13 (11) 1.00 1.00 15 (9) 1.00 1.00
PODXL high 43 (40) 1.78 (1.03–3.07) 1.25 (0.61–2.60) 35 (32) 1.12 (0.56–2.24) 0.79 (0.31–1.97) 8 (8) 2.90 (1.03–8.18) 4.77 (1.02–22.33)
Table 1. Unadjusted and adjusted hazard ratios of overall survival according to PODXL and EGFR expression 
in Cohort 1. Multivariable analysis adjusted for tumor morphology (entire cohort), tumor grade, T-stage (T1–2 
vs. T3–4), N-stage (N0 vs. N1), perineural growth, lymphatic invasion, blood vessel invasion, invasion of 
peripancreatic fat and adjuvant treatment. Statistically significant values displayed in bold text.
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appears to influence EGFR expression but not vice versa and, furthermore, that PODXL suppression can prevent 
the overexpression induced by TGF-β.
Discussion
The prognosis for patients with pancreatic and other periampullary adenocarcinomas remains poor with 
few treatment options. Thus, identifying biomarkers to better understand and define this group of tumors in 
a clinically relevant context is important. In this translational study we investigated PODXL and EGFR and 
demonstrated a significant relationship between the overexpression of these proteins in pancreatic and other 
periampullary adenocarcinomas. In the cohort comprising the full range of periampullary cancers, this associa-
tion was particularly evident in I-type tumors, whereas in PB-type tumors, all patients exhibited a similarly poor 
prognosis. However, in Cohort 2, which comprised only ductal pancreatic cancer, patients with tumors overex-
pressing both PODXL and EGFR exhibited a significantly shorter overall survival. The association between the 
overexpression of PODXL and EGFR seen in I-type periampullary tumors was not confirmed in PB-type tumors 
or in pancreatic cancer in Cohort 2 in the Cox regression analysis, further indicating that I-type tumors resemble 
and should be treated as colorectal cancer25.
The results from the tumor analyses were further verified through the in vitro data. Incubation with TGF-β 
rendered pancreatic cancer cells seemingly more invasive, leading to an increased expression of PODXL, par-
ticularly at the invasive front. This confirms that PODXL is markedly increased during TGF-β-induced EMT, a 
Figure 3. Overall survival according to PODXL and EGFR expressions in Cohort 2. Kaplan-Meier estimates 
for the overall survival in pancreatic ductal adenocarcinoma according to the combined strata of low and high 




HR (95%CI) HR (95%CI)
EGFR low
PODXL low 57 (44) 1.00 1.00
PODXL high 38 (31) 1.48 (0.94–2.31) 1.27 (0.75–2.16)
EGFR high
PODXL low 18 (16) 1.00 1.00
PODXL high 30 (26) 1.05 (0.57–1.93) 1.25 (0.59–2.65)
Table 2. Unadjusted and adjusted hazard ratios of overall survival according to PODXL and EGFR expression 
in Cohort 2. Multivariable analysis adjusted for tumor grade, T-stage (T1–2 vs. T3–4), N-stage (N0 vs. N1), 
perineural growth, blood vessel invasion and adjuvant treatment. Statistically significant values displayed in 
bold text.
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process associated with cell migration and increased invasion, as previously described by e.g. Meng et al.19 and 
Fröse et al.36. In addition, TGF-β has been associated with EMT in pancreatic cancer37, representing a central 
pathway in the development of pancreatic cancer38–40. The influence of TGF-β on PODXL and tumor aggres-
siveness might provide an explanation of the mechanism indicative of the association between high PODXL 
and reduced survival among patients. For instance, a study by Javle et al.41 demonstrated that a high plasma level 
of TGF-β1 was associated with diminished survival among patients with advanced pancreatic cancer. Notably 
in our study, while the knockdown of PODXL reduced EGFR expression, PODXL levels were not affected by 
the knockdown of EGFR. This was further confirmed in the presence of TGF-β, where siPODXL prevented an 
increase in PODXL and EGFR but siEGFR played no effect on protein expression. This agrees with our findings 
in both cohorts, where high PODXL expressing tumors were also more likely to display high levels of EGFR. 
Furthermore, EGFR signaling has been shown to take part in cancer progression, in that EGFR overexpression 
leads to enhanced invasiveness through the loss of E-cadherin42. Accordingly, inhibiting EGFR may affect EMT 
and inhibit cancer cell migration, although the association between EGFR and EMT is not as apparent as it is for 
PODXL. Moreover, the relationship between PODXL and EGFR is not fully understood, but previous in vitro 
studies have demonstrated a possible interaction through the Na+/H+ Exchanger Regulatory Factor (NHERF) 
proteins. Expression of PODXL leads to the induction of the NHERF proteins to the surface of the epithelial cell43. 
On the cell surface, NHERF-1 has been demonstrated to stabilize EGFR, thus restricting receptor downregula-
tion, leading to enhanced EGFR signaling44.
The response to EGFR inhibitors in e.g. non-small cell lung cancer depends upon specific EGFR mutations45, 
which are rare in pancreatic cancer22. Furthermore, in a phase III trial among patients with locally advanced or 
metastatic pancreatic cancer, the EGFR expression did not predict the response to the EGFR tyrosine kinase 
Figure 4. Effects of TGF-β incubation and siRNA-mediated silencing of PODXL and EGFR in pancreatic 
cancer cells. (A) 3D organotypic model of the PANC-1 cell line on gel sections, as visualized in an H&E stain 
(top row), without (left column) and after (right column) incubation with TGF-β. As shown in the second row, 
the expression of PODXL increases upon incubation with TGF-β, particularly along the invasive front (inserts 
show the immunocytochemistry on cell pellets). The third row shows that the expression of EGFR does not 
markedly change upon incubation with TGF-β. The fourth row shows the EGFR protein expression in siPODXL 
silenced PANC-1 cells and the bottom panel shows PODXL protein expression in siEGFR silenced PANC-1 
cells. (B) qPCR demonstrating the mRNA levels of PODXL and EGFR in siPODXL and siEGFR PANC-1 cell 
line. (C) qPCR demonstrating the mRNA levels of PODXL and EGFR in TGF-β incubated PANC-1 cell line. 
(D) qPCR demonstrating mRNA levels of PODXL and EGFR where PANC-1 cells were incubated with TGF-β 
following siRNA transfection.
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inhibitor erlotinib, when added to gemcitabine46. In addition, a study by Izumchenko et al.47 demonstrated a 
mechanism of how resistance to erlotinib may develop. During TGF-β-mediated EMT the microRNAs 200 
(miR200) family was inhibited and the expression of the mitogen-inducible gene 6 (MIG6), which is a negative 
regulator of EGFR, was upregulated, thus leading to resistance to erlotinib. The interaction between PODXL and 
EGFR and the potential role of PODXL in upregulating EGFR found in the present study is noteworthy, and it 
would be of interest to explore if PODXL expression affects the response to anti-EGFR directed therapy.
Since periampullary cancers encompass several different tumor origins, a pancreatic cancer cell line was cho-
sen for the in vitro portion of this study. This decision was made based on the fact that pancreatic cancer repre-
sented the largest subset of cancers among the periampullary tumors in Cohort 1, whereby Cohort 2 only includes 
ductal pancreatic cancers. The cell line, PANC-1, used here was obtained from a ductal pancreatic carcinoma 
from a 56-year old Caucasian male48. The tumor cells are TP53- and KRAS- mutated, but SMAD-4 wild type. 
Mutations in the tumor suppressor gene TP53 and the proto-oncogene KRAS lead to cell cycle deregulation, 
inhibition of apoptosis, cell invasion, metastasis and poor treatment response, all essential in tumor develop-
ment. Other cell lines currently used to study pancreatic carcinogenesis include MIA PaCa-2 and BxPC-3. When 
designing this study, these other cell lines were considered. However, the MIA PaCa-2 cell line has an impaired 
TGF-βR2 status, thus rendering it unsuitable for the experimental setting with TGF-β stimulation used herein, 
and BxPC-3 is KRAS wild-type48. Since KRAS mutations occur in almost all primary tumors of pancreatic cancer, 
and appear early in the progression of the disease, this cell line was also deemed unsuitable49.
One strength of this study stems from its use of two well-characterized, consecutive, and comparatively large 
patient cohorts with periampullary adenocarcinomas, including pancreatic cancer, both spanning over the same 
period of time. The cohorts were kept separate whereby the use of two different cohorts can be considered a vali-
dation of the results. Furthermore, given the fact that differentiation of tumor origin can be difficult in the clinical 
setting, using the morphological type in treatment decisions is crucial. All histological samples were re-evaluated 
by experienced pathologists, and clinical follow-up and survival data were reliable and up-to-date.
A potential limitation to this study lies in the use of TMA, since this technique, although being a well-validated 
method50, may not reflect heterogeneous biomarker expression. However, the analysis of one whole tissue section 
will also merely reflect a small portion of the tumor, and sampling of tissue cores from multiple donor blocks, 
carried out in this study, may provide a more representative picture of the entire tumor.
We have previously demonstrated that patients with I-type, but not PB-type, tumors displaying high expres-
sion of PODXL benefitted from adjuvant chemotherapy10. Furthermore, in patients with PB-type tumors receiv-
ing adjuvant gemcitabine, high expression of EGFR was significantly associated with a shorter overall survival 
and recurrence free survival, with a significant treatment interaction in relation to OS28. These findings suggest 
that adjuvant treatment has a limited or no effect on survival in patients with PB-type tumors with a high EGFR 
and PODXL expression. Speculatively, the inhibition of EGFR might serve as an alternative treatment option 
for these patients.
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